Japan Q2 Roundup: Mixed Bag For Majors But Forex Provides Boost

 
• By Lisa Takagi

Japan's top pharma firms logged generally strong performances for mainstay global drugs in the fiscal period ended 30 September, with the weakened yen adding substantially to figures for those with large overseas sales. Astellas and Eisai are among those awaiting important global-first approvals for potential blockbusters.

Quarterly financial results by Five Japanese firms showed high forex impacts with contrasting R&D view.
Japan's major pharma firms benefit from weak yen in latest quarter • Source: Shutterstock

More from Japan

More from Focus On Asia